Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  American Journal of Cardiology

• Publication date

  2001-09-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0002-9149(01)01813-6PMID 11564394
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Predictive value of C-reactive protein and troponin T in patients with unstable angina: A comparative analysis

  2000cited by this paper
• Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial.

  2000cited by this paper
• Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability.

  1999cited by this paper
• Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty.

  1999cited by this paper
• The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions.

  1998cited by this paper
• Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation.

  1998cited by this paper
• Predictive value of C-reactive protein after successful coronary-artery stenting in patients with stable angina.

  1998cited by this paper

• The role of P2Y12 receptor in ischemic stroke of atherosclerotic origin

  2018cites this paper
• Scoring system to predict early carotid restenosis after eversion endarterectomy by analysis of inflammatory markers

  2018cites this paper
• High-sensitive C-reactive protein and dual antiplatelet in intracranial arterial stenosis

  2018cites this paper
• The Effects of Antiplatelet, Antithrombotic, and Thrombolytic Agents on Inflammation and Circulating Inflammatory Biomarkers

  2016cites this paper
• he Yin and Yang f Arterial Inflammation

  2016cites this paper
• Myocardial Ischemia and Infarction lopidogrel Inhibits Platelet-Leukocyte nteractions and Thrombin Receptor gonist Peptide-Induced Platelet Activation n Patients With an Acute Coronary Syndrome

  2016cites this paper
• The inflammatory response to percutaneous coronary intervention is related to the technique of stenting and not the type of stent

  2016cites this paper
• The Versatile Platelet in Critical Illness

  2015cites this paper
• Platelets, inflammation and anti-inflammatory effects of antiplatelet drugs in ACS and CAD

  2015cites this paper
• Effects of Clopidogrel Therapy on Oxidative Stress, Inflammation, Vascular Function, and Progenitor Cells in Stable Coronary Artery Disease

  2014cites this paper
• Neoatherosclerosis: a novel player in late stent failure

  2014cites this paper
• Association of baseline C‐reactive protein levels with periprocedural myocardial injury in patients undergoing percutaneous bifurcation intervention: A CACTUS study subanalysis

  2014cites this paper
• Pharmacology of the New P2Y12 Receptor Inhibitors: Insights on Pharmacokinetic and Pharmacodynamic Properties

  2013cites this paper
• Therapies targeting inflammation after stent implantation.

  2013cites this paper
• Roles of Purinergic Receptor P2Y, G Protein–Coupled 12 in the Development of Atherosclerosis in Apolipoprotein E–Deficient Mice

  2012cites this paper
• Role of C-reactive protein in acute myocardial infarction and stroke: possible therapeutic approaches.

  2012cites this paper
• P2Y purinoceptors as potential emerging therapeutical target in vascular disease.

  2012cites this paper
• Anti-inflammatory effects of anti-platelet treatment in atherosclerosis.

  2012cites this paper
• Relationship Between Plasma Inflammatory Markers and Platelet Aggregation in Patients With Clopidogrel Resistance After Angioplasty

  2012cites this paper
• Markers of Endothelial Activation and Impaired Autonomic Function in Patients with Acute Coronary Syndromes – Potential Prognostic and Therapeutic Implication

  2012cites this paper
• The EFFect of hIgh-dose ClopIdogrel treatmENT in patients with clopidogrel resistance (the EFFICIENT trial).

  2012cites this paper
• A Guide to Drug Use During Percutaneous Coronary Intervention

  2012cites this paper
• Clopidogrel

  2012cites this paper
• Platelets and Atherothrombosis: An Essential Role for Inflammation in Vascular Disease — A Review

  2011cites this paper
• The effect of the duration of clopidogrel use on hsCRP levels after stenting the target vessel in patients with acute coronary syndrome.

  2011cites this paper
• Beyond Thrombosis

  2011cites this paper
• Effect of clopidogrel withdrawal on platelet reactivity and vascular inflammatory biomarkers 1 year after drug-eluting stent implantation: results of the prospective, single-centre CESSATION study

  2011cites this paper
• Inflammation as a Marker for the Prediction of Internal Carotid Artery Restenosis Following Eversion Endarterectomy—Evidence From Clinical Studies

  2011cites this paper
• Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment

  2010cites this paper
• Impact of inflammatory markers on platelet inhibition and cardiovascular outcome including stent thrombosis in patients with symptomatic coronary artery disease.

  2010cites this paper
• Clopidogrel and endothelial injury after percutaneous coronary interventions: beyond the antiplatelet effects.

  2010cites this paper
• Role of the P2Y12 Receptor in the Modulation of Murine Dendritic Cell Function by ADP

  2010cites this paper
• Predictive value of C-reactive protein after drug-eluting stent implantation.

  2010cites this paper
• Function by ADP Modulation of Murine Dendritic Cell Receptor in the 12 Role of the P2Y

  2010cites this paper
• [Which cut-off value of high sensitivity C- reactive protein is more valuable for determining long- term prognosis in patients with acute coronary syndrome?].

  2009cites this paper
• Randomized Controlled Trial Following Percutaneous Coronary Intervention: A Early and Sustained Dual Oral Antiplatelet Therapy

  2009cites this paper
• Relationship Between Baseline Inflammatory Markers, Antiplatelet Therapy, and Adverse Cardiac Events After Percutaneous Coronary Intervention: An Analysis From the Clopidogrel for the Reduction of Events During Observation Trial

  2009cites this paper
• P roclaim Pilot Study to Examine the Effects of Clopidogrel on Inflammatory Markers in Patients with Metabolic Syndrome Receiving Low-Dose Aspirin ben-ClinicalInvestigation

  2009cites this paper
• PROCLAIM: pilot study to examine the effects of clopidogrel on inflammatory markers in patients with metabolic syndrome receiving low-dose aspirin.

  2009cites this paper
• Impact of thienopyridine administration prior to primary stenting in acute myocardial infarction.

  2009cites this paper
• Efficacy of Clopidrogel on Reperfusion and High-Sensitivity C-Reactive Protein in Patients with Acute Myocardial Infarction

  2009cites this paper
• Beyond platelet inhibition: potential pleiotropic effects of ADP-receptor antagonists

  2009cites this paper
• Aspirin and Platelet Adenosine Diphosphate Receptor Antagonists in Acute Coronary Syndromes and Percutaneous Coronary Intervention

  2008cites this paper
• Efekti Konvencionalne I Agresivnije Terapije Rosuvastatinom na Markere Endotelne Aktivacije

  2008cites this paper
• Effect of Conventional and More Aggressive Rosuvastatin Treatment on Markers of Endothelial Activation

  2008cites this paper
• Determining the efficacy of antiplatelet therapies for the individual: lessons from clinical trials

  2008cites this paper
• Pre-procedural C-reactive protein levels and clinical outcomes after percutaneous coronary interventions with and without abciximab: pooled analysis of four ISAR trials

  2008cites this paper
• New evidences for C-reactive protein (CRP) deposits in the arterial intima as a cardiovascular risk factor

  2008cites this paper
• Platelets as mediators of inflammation.

  2007cites this paper
• Progress in Clinical Neurosciences: The ‘Antiplatelet’ Agents and the Role of the Endothelium

  2007cites this paper
• C-reactive protein: interaction with the vascular endothelium and possible role in human atherosclerosis.

  2007cites this paper
• Evaluation of C-Reactive Protein in Primary and Secondary Prevention

  2007cites this paper
• Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease

  2007cites this paper
• Relation between impaired antiplatelet response to clopidogrel and possible pleiotropic effects

  2007cites this paper
• Clopidogrel versus Acetylsalicylsäure in der Sekundärprophylaxe vaskulärer Erkrankungen

  2007cites this paper
• Does pravastatin therapy affect cardiac enzyme levels after percutaneous coronary intervention?

  2007cites this paper
• Naproxen treatment prevents periprocedural inflammatory response but not myocardial injury after percutaneous coronary intervention.

  2007cites this paper
• Prolonged application of clopidogrel reduces inflammation after percutaneous coronary intervention in the porcine model.

  2007cites this paper
• Safety and efficacy of low-dose unfractionated heparin during percutaneous coronary revascularisation and the relationship between activated clotting time and haemorrhagic or ischaemic complications: our results

  2006cites this paper
• Critical Appraisal of C-Reactive Protein Throughout the Spectrum of Cardiovascular Disease

  2006cites this paper
• Relation between soluble intercellular adhesion molecule-1, statin therapy, and long-term risk of clinical cardiovascular events in patients with previous acute coronary syndrome (from PROVE IT-TIMI 22).

  2006cites this paper
• A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial.

  2006cites this paper
• Antiplatelet Therapy after Percutaneous Coronary Intervention

  2006cites this paper
• Divergent effects of rofecoxib on endothelial function and inflammation in acute coronary syndromes.

  2006cites this paper
• Antiplatelet Therapy after Percutaneous Coronary Intervention

  2006cites this paper
• Inflammation, Atherosclerosis, and Stroke

  2006cites this paper
• Actions of Insulin Stimulatory Promotes glucose transport into cells Enhances glycogen synthesis Increases fatty acid synthesis Promotes protein synthesis Modifies cellular differentiation and proliferation Inhibitory Inhibits gluconeogenesis Reduces hepatic glucose output Inhibits

  2006cites this paper
• The potential role of antiplatelet agents in modulating inflammatory markers in atherothrombosis

  2006cites this paper
• C-Reactive Protein as a Tool for Risk Assessment in Primary Prevention

  2006cites this paper
• Preprocedural C-reactive protein levels predict myocardial necrosis after successful coronary stenting in patients with stable angina.

  2006cites this paper
• Antiplatelet agents: current drugs and future trends.

  2005cites this paper
• Clopidogrel for the secondary prevention of stroke

  2005cites this paper
• Randomized Trial of High Loading Dose of Clopidogrel for Reduction of Periprocedural Myocardial Infarction in Patients Undergoing Coronary Intervention: Results From the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study*

  2005cites this paper
• Bisphosphonates as anti-inflammatory agents in ankylosing spondylitis and spondylarthropathies

  2005cites this paper
• Oral antiplatelet therapy and percutaneous coronary intervention

  2005cites this paper
• Enhancing reperfusion therapy for myocardial infarction with dual antiplatelet therapy: Breaking the glass ceiling.

  2005cites this paper
• Relationship between C-Reactive Protein and the Electrocardiographic Pattern on Admission in Patients with Acute Coronary Syndrome

  2005cites this paper
• Does creatinine kinase-MB elevation after percutaneous coronary intervention predict outcomes in 2005? Periprocedural cardiac enzyme elevation predicts adverse outcomes.

  2005cites this paper
• Coronary stenting and inflammation.

  2005cites this paper
• Effects of weight loss and pharmacotherapy on inflammatory markers of cardiovascular disease

  2005cites this paper
• Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trial

  2005cites this paper
• Antiplatelet Agents in Patients Undergoing Percutaneous Coronary Intervention

  2005cites this paper
• One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel.

  2005influential citation
• Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study.

  2005cites this paper
• New approaches in the intensive management of cardiovascular risk in the metabolic syndrome.

  2005cites this paper
• Percutaneous coronary intervention and adjunctive pharmacotherapy in women: a statement for healthcare professionals from the American Heart Association.

  2005cites this paper
• Valoración de la proteína C reactiva en pacientes con arteriopatía periférica. Modificaciones con tratamiento antiagregante

  2005cites this paper
• Comparison of Clopidogrel versus Cilostazol in CoronaryArtery Stenting

  2005cites this paper
• Platelets and atherothrombosis: An essential role for inflammation in vascular disease — A review

  2005cites this paper
• Myocardial Ischemia and Infarction Clopidogrel Inhibits Platelet-Leukocyte Interactions and Thrombin Receptor Agonist Peptide-Induced Platelet Activation in Patients With an Acute Coronary Syndrome

  2004cites this paper
• Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention.

  2004cites this paper
• Prevention of restenosis after stenting: the emerging role of inflammation

  2004cites this paper
• Risk stratification and the management of non-ST-segment elevation acute coronary syndromes: the role of antiplatelet therapy.

  2004cites this paper
• Inflammation and cardiovascular diseases: lessons that can be learned for the patient with cardiogenic shock in the intensive care unit

  2004cites this paper
• Loading With 600 mg Clopidogrel in Patients With Coronary Artery Disease With and Without Chronic Clopidogrel Therapy

  2004cites this paper
• Inflammation and atherosclerosis

  2004cites this paper
• The Yin and Yang of arterial inflammation.

  2004cites this paper
• Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.

  2004cites this paper
• Focusing on Inflammation in the Treatment of Atherosclerosis

  2004cites this paper
• The role of inflammation in atherothrombosis: current and future strategies of medical treatment.

  2004cites this paper